ログイン
言語:

WEKO3

  • トップ
  • コミュニティ
  • ランキング
AND
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "6ce664ab-98b9-47bf-a3c9-b21bf043e5b7"}, "_deposit": {"id": "6497", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "6497"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00006497"}, "item_7_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1994-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "128", "bibliographicPageStart": "123", "bibliographicVolumeNumber": "42", "bibliographic_titles": [{"bibliographic_title": "Acta medica et biologica"}, {"bibliographic_title": "Acta medica et biologica", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "In order to assess its effects on blood pressure and serum lipids, doxazosin was administered to patients with essential hypertension and a serum total cholesterol level above 220 mg/dl as part of a multicenter trial in which 7 institutions in Niigata Prefecture participated. Doxazosin was given either as monotherapy or in combination with some other antihypertensive agent. The systolic, diastolic, and mean blood pressures were all decreased significantly at weeks 4, 8 and 12 of treatment, while there was no change in the heart rate throughout the study. The antihypertensive effects in individual patients were rated according to the \"Guideline for Clinical Evaluation of Antihypertensive Drugs.\" Moderate or improved reduction of blood pressure was attained in 29/39 patients (74%) after 12 weeks of treatment. Total cholesterol and low density lipoprotein (LDL) cholesterol levels decreased significantly after doxazosin treatment, while the cholesterol ratio (high density lipoprotein (HDL) cholesterol/total cholesterol) increased significantly. Although the apoprotein A_1 level remained unchanged, the apoprotein B level decreased significantly, and the apoprotein A_1/apoprotein B ratio increased significantly as a consequence. These results suggest that doxazosin is a useful antihypertensive drug which may be used as a first choice therapy in patients with essential hypertension and high serum cholesterol level.", "subitem_description_type": "Abstract"}]}, "item_7_publisher_7": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "Niigata University School of Medicine"}]}, "item_7_select_19": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00508361", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "05677734", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Watanabe, Kenichi"}], "nameIdentifiers": [{"nameIdentifier": "53212", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hirokawa, Yoichi"}], "nameIdentifiers": [{"nameIdentifier": "53213", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hirosawa, Hideo"}], "nameIdentifiers": [{"nameIdentifier": "53214", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohara, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "53215", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamimura, Akira"}], "nameIdentifiers": [{"nameIdentifier": "53216", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshida, Hideharu"}], "nameIdentifiers": [{"nameIdentifier": "53217", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Furukawa, Nobuo"}], "nameIdentifiers": [{"nameIdentifier": "53218", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shibata, Akira"}], "nameIdentifiers": [{"nameIdentifier": "53219", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-06"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "42(3)_123-128.pdf", "filesize": [{"value": "598.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 598100.0, "url": {"label": "42(3)_123-128.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/6497/files/42(3)_123-128.pdf"}, "version_id": "778013c8-92dd-4ee8-86cf-8362586b7ae8"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Effects of Doxazosin Mesilate on Blood Pressure and Serum Lipids in Hypertensive Patients", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Effects of Doxazosin Mesilate on Blood Pressure and Serum Lipids in Hypertensive Patients"}, {"subitem_title": "Effects of Doxazosin Mesilate on Blood Pressure and Serum Lipids in Hypertensive Patients", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["453/456", "471/537/568/626"], "permalink_uri": "http://hdl.handle.net/10191/33249", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_value": "2015-09-04"}, "publish_date": "2015-09-04", "publish_status": "0", "recid": "6497", "relation": {}, "relation_version_is_last": true, "title": ["Effects of Doxazosin Mesilate on Blood Pressure and Serum Lipids in Hypertensive Patients"], "weko_shared_id": null}
  1. 0 資料タイプ別
  2. 03 紀要論文
  1. 250 大学院医歯学総合研究科(医)
  2. 20 紀要
  3. 01 Acta medica et biologica
  4. Vol.42 No.3

Effects of Doxazosin Mesilate on Blood Pressure and Serum Lipids in Hypertensive Patients

http://hdl.handle.net/10191/33249
b76ac844-4a0b-4832-8514-3bb0352dccf3
名前 / ファイル ライセンス アクション
42(3)_123-128.pdf 42(3)_123-128.pdf (598.1 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2015-09-04
タイトル
タイトル Effects of Doxazosin Mesilate on Blood Pressure and Serum Lipids in Hypertensive Patients
タイトル
言語 en
タイトル Effects of Doxazosin Mesilate on Blood Pressure and Serum Lipids in Hypertensive Patients
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
著者 Watanabe, Kenichi

× Watanabe, Kenichi

WEKO 53212

Watanabe, Kenichi

Search repository
Hirokawa, Yoichi

× Hirokawa, Yoichi

WEKO 53213

Hirokawa, Yoichi

Search repository
Hirosawa, Hideo

× Hirosawa, Hideo

WEKO 53214

Hirosawa, Hideo

Search repository
Ohara, Kazuhiko

× Ohara, Kazuhiko

WEKO 53215

Ohara, Kazuhiko

Search repository
Kamimura, Akira

× Kamimura, Akira

WEKO 53216

Kamimura, Akira

Search repository
Yoshida, Hideharu

× Yoshida, Hideharu

WEKO 53217

Yoshida, Hideharu

Search repository
Furukawa, Nobuo

× Furukawa, Nobuo

WEKO 53218

Furukawa, Nobuo

Search repository
Shibata, Akira

× Shibata, Akira

WEKO 53219

Shibata, Akira

Search repository
抄録
内容記述タイプ Abstract
内容記述 In order to assess its effects on blood pressure and serum lipids, doxazosin was administered to patients with essential hypertension and a serum total cholesterol level above 220 mg/dl as part of a multicenter trial in which 7 institutions in Niigata Prefecture participated. Doxazosin was given either as monotherapy or in combination with some other antihypertensive agent. The systolic, diastolic, and mean blood pressures were all decreased significantly at weeks 4, 8 and 12 of treatment, while there was no change in the heart rate throughout the study. The antihypertensive effects in individual patients were rated according to the "Guideline for Clinical Evaluation of Antihypertensive Drugs." Moderate or improved reduction of blood pressure was attained in 29/39 patients (74%) after 12 weeks of treatment. Total cholesterol and low density lipoprotein (LDL) cholesterol levels decreased significantly after doxazosin treatment, while the cholesterol ratio (high density lipoprotein (HDL) cholesterol/total cholesterol) increased significantly. Although the apoprotein A_1 level remained unchanged, the apoprotein B level decreased significantly, and the apoprotein A_1/apoprotein B ratio increased significantly as a consequence. These results suggest that doxazosin is a useful antihypertensive drug which may be used as a first choice therapy in patients with essential hypertension and high serum cholesterol level.
書誌情報 Acta medica et biologica
en : Acta medica et biologica

巻 42, 号 3, p. 123-128, 発行日 1994-09
出版者
出版者 Niigata University School of Medicine
ISSN
収録物識別子タイプ ISSN
収録物識別子 05677734
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AA00508361
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 19:37:06.255816
Show All versions

Share

Mendeley CiteULike Twitter Facebook Print Addthis

Cite as

Export

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by CERN Data Centre & Invenio


Powered by CERN Data Centre & Invenio